{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T08:12:15Z","timestamp":1794989535270,"version":"4.9.1"},"reference-count":41,"publisher":"American Association for Cancer Research (AACR)","issue":"2","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>CAN-2409 is a replication-defective adenovirus that delivers the herpes simplex virus\u2013thymidine kinase gene to infected cells. Intratumoral administration of CAN-2409, followed by prodrug, results in the formation of a toxic metabolite able to induce immunogenic cell death, exposure of tumor-associated antigens, and activation of local and systemic immune responses. We used a dynamic labeling model with MC38 tumor cells implanted in photoconvertible Kaede mice. Violet light was used to label the tumor microenvironment (TME), distinguishing retained versus newly entering cells and allowing real-time monitoring of immune compartment changes within tumors. Administration of CAN-2409 + prodrug led to control of tumor growth and significantly increased effector CD8+ T-cell responses. Photolabeling of the TME revealed that rather than enhancing recruitment of T cells to the tumor, CAN-2409 altered the TME whereby newly entering and retained CD8+ T cells were significantly more proliferative. CAN-2409 supported reinvigoration of tumor-associated antigen\u2013specific CD8+ T cells and expansion of regulatory T cells of an altered phenotype. Moreover, the combination of CAN-2409 + prodrug and anti\u2013CTLA-4 antibody treatment further improved control of tumor growth, in part by the enhanced CD8+ T-cell\u2013mediated effector function and diminished regulatory T cell\u2013mediated immunosuppression. Collectively, these data defined at least two temporally distinct pathways underpinning the mechanism of action of CAN-2409 that overcome cell exhaustion and decrease immune suppression. The results also support the rationale for future clinical trials of CAN-2409 treatment combined with anti\u2013CTLA-4 antibody therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This study utilized a novel photoconvertible mouse tumor model to track immune cell trafficking upon treatment with an investigational viral immunotherapy (CAN-2409), revealing enhanced T-cell responses after viral immunotherapy associated with local proliferation of T cells within tumors that could further enhance antitumor efficacy in combination with immune checkpoint inhibitors. These findings define temporally and spatially distinct interactions of immune cells that could be harnessed by novel therapeutics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-24-0434","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T02:48:47Z","timestamp":1738205327000},"page":"327-338","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0920-0549","authenticated-orcid":false,"given":"Anne R.","family":"Diers","sequence":"first","affiliation":[{"name":"1Candel Therapeutics, Inc., Needham, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5332-4752","authenticated-orcid":false,"given":"Qiuchen","family":"Guo","sequence":"additional","affiliation":[{"name":"1Candel Therapeutics, Inc., Needham, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0583-1116","authenticated-orcid":false,"given":"Zhi","family":"Li","sequence":"additional","affiliation":[{"name":"2Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8631-8254","authenticated-orcid":false,"given":"Erin","family":"Richardson","sequence":"additional","affiliation":[{"name":"2Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6070-4670","authenticated-orcid":false,"given":"Suaad","family":"Idris","sequence":"additional","affiliation":[{"name":"2Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5504-6741","authenticated-orcid":false,"given":"Claire","family":"Willis","sequence":"additional","affiliation":[{"name":"2Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3532-5409","authenticated-orcid":false,"given":"Paul P.","family":"Tak","sequence":"additional","affiliation":[{"name":"1Candel Therapeutics, Inc., Needham, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3757-7594","authenticated-orcid":false,"given":"David R.","family":"Withers","sequence":"additional","affiliation":[{"name":"2Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5287-9614","authenticated-orcid":false,"given":"Francesca","family":"Barone","sequence":"additional","affiliation":[{"name":"1Candel Therapeutics, Inc., Needham, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"2025051308560743100_bib1","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"2025051308560743100_bib2","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"2025051308560743100_bib3","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1053\/hupa.2000.8453","article-title":"Cytopathic effect of in situ gene therapy in prostate cancer","volume":"31","author":"Ayala","year":"2000","journal-title":"Hum Pathol"},{"key":"2025051308560743100_bib4","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.ymthe.2020.11.001","article-title":"Neoadjuvant gene-mediated cytotoxic immunotherapy for non-small-cell lung cancer: safety and immunologic activity","volume":"29","author":"Predina","year":"2021","journal-title":"Mol Ther"},{"key":"2025051308560743100_bib5","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/cgt.2011.56","article-title":"Neoadjuvant in situ gene-mediated cytotoxic immunotherapy improves postoperative outcomes in novel syngeneic esophageal carcinoma models","volume":"18","author":"Predina","year":"2011","journal-title":"Cancer Gene Ther"},{"key":"2025051308560743100_bib6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1756-8722-5-34","article-title":"Cytoreduction surgery reduces systemic myeloid suppressor cell populations and restores intratumoral immunotherapy effectiveness","volume":"5","author":"Predina","year":"2012","journal-title":"J Hematol Oncol"},{"key":"2025051308560743100_bib7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/neuonc\/nox139","article-title":"Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma","volume":"20","author":"Speranza","year":"2018","journal-title":"Neuro-Oncology"},{"key":"2025051308560743100_bib8","doi-asserted-by":"crossref","first-page":"4348","DOI":"10.1073\/pnas.91.10.4348","article-title":"Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors","volume":"91","author":"Barba","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025051308560743100_bib9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/(SICI)1097-0215(19970117)70:2<183::AID-IJC8>3.0.CO;2-T","article-title":"Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer","volume":"70","author":"Hall","year":"1997","journal-title":"Int J Cancer"},{"key":"2025051308560743100_bib10","first-page":"6228","article-title":"Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component","volume":"54","author":"Vile","year":"1994","journal-title":"Cancer Res"},{"key":"2025051308560743100_bib11","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2011.35.5222","article-title":"Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma","volume":"29","author":"Chiocca","year":"2011","journal-title":"J Clin Oncol"},{"key":"2025051308560743100_bib12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1006\/mthe.2000.0030","article-title":"Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors","volume":"1","author":"Trask","year":"2000","journal-title":"Mol Ther"},{"key":"2025051308560743100_bib13","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1089\/10430349950018229","article-title":"In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial","volume":"10","author":"Herman","year":"1999","journal-title":"Hum Gene Ther"},{"key":"2025051308560743100_bib14","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0022-5347(05)67534-9","article-title":"Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer","volume":"163","author":"Shalev","year":"2000","journal-title":"J Urol"},{"key":"2025051308560743100_bib15","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/sj.cgt.7700192","article-title":"Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer","volume":"7","author":"Hasenburg","year":"2000","journal-title":"Cancer Gene Ther"},{"key":"2025051308560743100_bib16","doi-asserted-by":"crossref","first-page":"7927","DOI":"10.1200\/JCO.2004.00.1883","article-title":"Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir","volume":"23","author":"Ch\u00e9vez-Barrios","year":"2005","journal-title":"J Clin Oncol"},{"key":"2025051308560743100_bib17","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00262-015-1679-3","article-title":"Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma","volume":"64","author":"Aguilar","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"2025051308560743100_bib18","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.ymthe.2018.02.015","article-title":"Phase I study of intrapleural gene-mediated cytotoxic immunotherapy in patients with malignant pleural effusion","volume":"26","author":"Aggarwal","year":"2018","journal-title":"Mol Ther"},{"key":"2025051308560743100_bib19","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/neuonc\/noy202","article-title":"Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma","volume":"21","author":"Kieran","year":"2019","journal-title":"Neuro Oncol"},{"key":"2025051308560743100_bib20","doi-asserted-by":"crossref","first-page":"207129","DOI":"10.1155\/2013\/207129","article-title":"Therapeutic endoscopic ultrasonography: intratumoral injection for pancreatic adenocarcinoma","volume":"2013","author":"Shirley","year":"2013","journal-title":"Gastroenterol Res Pract"},{"issue":"Suppl 16","key":"2025051308560743100_bib21","doi-asserted-by":"crossref","first-page":"9037","DOI":"10.1200\/JCO.2022.40.16_suppl.9037","article-title":"First report of safety\/tolerability and preliminary antitumor activity of CAN-2409 in inadequate responders to immune checkpoint inhibitors for stage III\/IV NSCLC","volume":"40","author":"Aggarwal","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Suppl 16","key":"2025051308560743100_bib22","doi-asserted-by":"crossref","first-page":"8634","DOI":"10.1200\/JCO.2024.42.16_suppl.8634","article-title":"Overall survival after treatment with CAN-2409 plus valacyclovir in combination with continued ICI in patients with stage III\/IV NSCLC with an inadequate response to ICI","volume":"42","author":"Aggarwal","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025051308560743100_bib23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.it.2017.11.006","article-title":"Antitumor benefits of antiviral immunity: an underappreciated aspect of oncolytic virotherapies","volume":"39","author":"Gujar","year":"2018","journal-title":"Trends Immunol"},{"key":"2025051308560743100_bib24","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1016\/j.celrep.2019.10.131","article-title":"Single-cell profiling defines transcriptomic signatures specific to tumor-reactive versus virus-responsive CD4+ T cells","volume":"29","author":"Magen","year":"2019","journal-title":"Cell Rep"},{"key":"2025051308560743100_bib25","doi-asserted-by":"crossref","first-page":"782852","DOI":"10.3389\/fimmu.2021.782852","article-title":"Antiviral responses in cancer: boosting antitumor immunity through activation of interferon pathway in the tumor microenvironment","volume":"12","author":"Vitiello","year":"2021","journal-title":"Front Immunol"},{"key":"2025051308560743100_bib26","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/s41467-024-44789-z","article-title":"Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity","volume":"15","author":"Dean","year":"2024","journal-title":"Nat Commun"},{"key":"2025051308560743100_bib27","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41467-024-44787-1","article-title":"Tumour-retained activated CCR7+ dendritic cells are heterogeneous and regulate local anti-tumour cytolytic activity","volume":"15","author":"Lee","year":"2024","journal-title":"Nat Commun"},{"key":"2025051308560743100_bib28","doi-asserted-by":"crossref","first-page":"e20210749","DOI":"10.1084\/jem.20210749","article-title":"In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue","volume":"219","author":"Li","year":"2022","journal-title":"J Exp Med"},{"key":"2025051308560743100_bib29","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.immuni.2019.11.002","article-title":"Proliferating transitory T cells with an effector-like transcriptional signature emerge from PD-1+ stem-like CD8+ T cells during chronic infection","volume":"51","author":"Hudson","year":"2019","journal-title":"Immunity"},{"key":"2025051308560743100_bib30","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41590-020-0760-z","article-title":"Early precursor T cells establish and propagate T cell exhaustion in chronic infection","volume":"21","author":"Utzschneider","year":"2020","journal-title":"Nat Immunol"},{"key":"2025051308560743100_bib31","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.immuni.2019.10.009","article-title":"CD4+ T cell help is required for the formation of a cytolytic CD8+ T cell subset that protects against chronic infection and cancer","volume":"51","author":"Zander","year":"2019","journal-title":"Immunity"},{"key":"2025051308560743100_bib32","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1073\/pnas.91.8.3054","article-title":"Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo","volume":"91","author":"Chen","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025051308560743100_bib33","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1089\/hum.1996.7.4-515","article-title":"Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models","volume":"7","author":"Eastham","year":"1996","journal-title":"Hum Gene Ther"},{"key":"2025051308560743100_bib34","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/jnr.490390417","article-title":"Adenovirus-mediated gene therapy of experimental gliomas","volume":"39","author":"Perez-Cruet","year":"1994","journal-title":"J Neurosci Res"},{"key":"2025051308560743100_bib35","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"2025051308560743100_bib36","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41568-023-00615-0","article-title":"Stem-like exhausted and memory CD8+ T cells in cancer","volume":"23","author":"Gebhardt","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"2025051308560743100_bib37","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","article-title":"Treg cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2025051308560743100_bib38","doi-asserted-by":"crossref","first-page":"731947","DOI":"10.3389\/fimmu.2021.731947","article-title":"Regulatory T cells in autoimmunity and cancer: a duplicitous lifestyle","volume":"12","author":"Hatzioannou","year":"2021","journal-title":"Front Immunol"},{"key":"2025051308560743100_bib39","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.trecan.2023.07.015","article-title":"Modulating Treg stability to improve cancer immunotherapy","volume":"9","author":"Kang","year":"2023","journal-title":"Trends Cancer"},{"key":"2025051308560743100_bib40","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"issue":"Suppl 2","key":"2025051308560743100_bib41","first-page":"A1535","article-title":"1477 First efficacy and multi-omic analysis data from phase 1 clinical trial of oncolytic viral immunotherapy with CAN-2409 + valacyclovir in combination with nivolumab and standard of care in newly diagnosed high-grade glioma","volume":"10","author":"Wen","year":"2022","journal-title":"J Immunother Cancer"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-24-0434\/3538124\/crc-24-0434.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/2\/327\/3542064\/crc-24-0434.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/2\/327\/3542064\/crc-24-0434.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T08:56:17Z","timestamp":1747126577000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/2\/327\/751784\/Dynamic-Tracking-of-Tumor-Microenvironment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-24-0434","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.29050771","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29050768","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29050765","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29050777","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29050774","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28427833","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28427821","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28427842","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28427830","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28427815","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28427836","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28427824","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28427812","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28427845","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28427818","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28427839","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28427827","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7676086","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,1]]}}}